TCGA-E5-A4TZ-01A-11R-A31N-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 15.34165572
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.550
- G2M_CHECKPOINT+0.540
- MITOTIC_SPINDLE+0.390
- MYC_TARGETS_V1+0.370
- PI3K_AKT_MTOR_SIGNALING+0.240
- MYC_TARGETS_V2+0.140
- SPERMATOGENESIS+0.140
- UNFOLDED_PROTEIN_RESPONSE+0.120
- DNA_REPAIR+0.070
- PROTEIN_SECRETION+0.070
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.680
- ANGIOGENESIS-0.650
- ALLOGRAFT_REJECTION-0.460
- TNFA_SIGNALING_VIA_NFKB-0.440
- KRAS_SIGNALING_UP-0.410
- INFLAMMATORY_RESPONSE-0.400
- MYOGENESIS-0.390
- HEDGEHOG_SIGNALING-0.380
- COAGULATION-0.350
- HYPOXIA-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR650141 | — | — | 0.918 |
| 2 | SRR650202 | — | — | 0.915 |
| 3 | TCGA-CV-5442-01A-01R-1514-07 | — | — | 0.904 |
| 4 | 53536_S130 | — | cohortSQ1 | 0.903 |
| 5 | C3L-04013 | — | cohortMD1 | 0.893 |
| 6 | TCGA-43-7658-01A-11R-2125-07 | — | cohortMD1 | 0.891 |
| 7 | SRR8942963 | — | — | 0.890 |
| 8 | TCGA-O2-A5IB-01A-11R-A27Q-07 | — | cohortMD1 | 0.889 |
| 9 | TCGA-E7-A5KE-01A-11R-A28M-07 | — | — | 0.885 |
| 10 | TCGA-66-2793-01A-01R-1201-07 | — | cohortMD1 | 0.881 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.550 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.540 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.390 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.370 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.240 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.140 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.120 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.070 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.070 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.030 | Inavolisib | — uncovered |